These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 34525199)

  • 21. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.
    van Ravenhorst MB; den Hartog G; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    PLoS One; 2018; 13(4):e0191261. PubMed ID: 29672552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world impact and effectiveness of MenACWY-TT.
    Villena R; Kriz P; Tin Tin Htar M; Burman C; Findlow J; Balmer P; Jodar L
    Hum Vaccin Immunother; 2023 Aug; 19(2):2251825. PubMed ID: 37679903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination.
    Bijlsma MW; Brouwer MC; Spanjaard L; van de Beek D; van der Ende A
    Clin Infect Dis; 2014 Nov; 59(9):1216-21. PubMed ID: 25069869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.
    Ilyina N; Kharit S; Namazova-Baranova L; Asatryan A; Benashvili M; Tkhostova E; Bhusal C; Arora AK
    Hum Vaccin Immunother; 2014; 10(8):2471-81. PubMed ID: 25424958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of routine immunization using meningococcal C conjugate vaccine on invasive meningococcal disease in British Columbia.
    Siu T; Tang W; Dawar M; Patrick DM
    Can J Public Health; 2008; 99(5):380-2. PubMed ID: 19009920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations.
    Martinón-Torres F; Taha MK; Knuf M; Abbing-Karahagopian V; Pellegrini M; Bekkat-Berkani R; Abitbol V
    Pathog Glob Health; 2022 Mar; 116(2):85-98. PubMed ID: 34569453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.
    Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP
    Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series.
    de Waure C; Miglietta A; Nedovic D; Mereu G; Ricciardi W
    Hum Vaccin Immunother; 2016; 12(2):467-73. PubMed ID: 26308192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
    Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N
    Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
    Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M
    Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
    Si S; Zomer E; Fletcher S; Lee J; Liew D
    Vaccine; 2019 Aug; 37(35):5009-5015. PubMed ID: 31301916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study.
    Ohm M; van Straalen JW; de Joode-Smink G; van Montfrans J; Bartels M; van Wildenbeest JG; Lindemans CA; Wennink RA; de Boer JH; Sanders EA; Verduyn-Lunel FM; Berbers GA; Wulffraat NM; Jansen MHA
    Pediatr Rheumatol Online J; 2023 Jul; 21(1):73. PubMed ID: 37475057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine.
    Keshavan P; Pellegrini M; Vadivelu-Pechai K; Nissen M
    Expert Rev Vaccines; 2018 Oct; 17(10):865-880. PubMed ID: 30198805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meningococcal W135 Disease Vaccination Intent, the Netherlands, 2018-2019.
    de Vries M; Claassen L; Te Wierik MJM; Coban F; Wong A; Timmermans DRM; Timen A
    Emerg Infect Dis; 2020 Jul; 26(7):1420-1429. PubMed ID: 32568034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model.
    Argante L; Abbing-Karahagopian V; Vadivelu K; Rappuoli R; Medini D
    BMC Infect Dis; 2021 Dec; 21(1):1244. PubMed ID: 34895161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
    Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
    Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of invasive meningococcal disease in university students in England and optimal strategies for protection using MenACWY vaccine.
    Mandal S; Campbell H; Ribeiro S; Gray S; Carr T; White J; Ladhani SN; Ramsay ME
    Vaccine; 2017 Oct; 35(43):5814-5818. PubMed ID: 28928076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.
    Ruiz Garcia Y; Abitbol V; Pellegrini M; Bekkat-Berkani R; Soumahoro L
    Infect Dis Ther; 2022 Apr; 11(2):639-655. PubMed ID: 34591258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Four-Component Recombinant Protein-Based Vaccine Effectiveness Against Serogroup B Meningococcal Disease in Italy.
    Lodi L; Barbati F; Amicizia D; Baldo V; Barbui AM; Bondi A; Costantino C; Da Dalt L; Ferrara L; Fortunato F; Guarnieri V; Icardi G; Indolfi G; Martinelli D; Martini M; Moriondo M; Nieddu F; Peroni DG; Prato R; Ricci S; Russo F; Tirelli F; Vitale F; Ladhani SN; Azzari C;
    JAMA Netw Open; 2023 Aug; 6(8):e2329678. PubMed ID: 37594762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.